Sign in
CompletedPhase 1

A Study to Evaluate the Safety and Immunogenicity of Two Doses of a Novel H5 Central Antigen mRNA-LNP in Healthy Adults

Key facts

Who runs it
National Institute of Allergy and Infectious Diseases (NIAID)
Where
Durham, Houston, and Nashville, United StatesSee the 3 sites
Trial code
Status
Completed
Phase
Phase 1
People taking part
80 people enrolled
Started
12 Jun 2025
Ended
22 May 2026
Type of study
Interventional, 5 groups
Treatments tested
  • H5 AC-Anhui RNA Vaccine
  • H5 Astrakhan RNA Vaccine
  • Sodium Chloride, 0.9%
Record updated
12 June 2026

Who can take part

Age
18 years to 49 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • Provides written informed consent prior to the initiation of any trial procedures
  • Can understand and agrees to comply with all planned trial procedures and be available for all study visits
  • Adult volunteers, age 18-49 years, inclusive, at time of enrollment
  • In good general health.* * Good health is defined by the absence of a medical condition described in the exclusion criteria. If the participant has another current, ongoing medical condition, the condition cannot meet any of the following criteria:; was first diagnosed within 3 months of enrollment with a clinically significant condition, in the opinion of investigator; had non-elective surgery, clinically significant medical procedure, or hospitalization within 3 months of enrollment; received new prescription for systemic medication within 30 days of enrollment, unless the new prescription is in the same class of agent or a transition from generic to/from brand name equivalent; or; takes medication that may pose a risk to participant's safety or impede assessment of adverse events or study endpoints if they participate in the study
  • Participants of childbearing potential* must agree to use or have practiced true abstinence** or use at least one acceptable primary form of contraception.*** *These criteria apply to females who are in a heterosexual relationship who are of childbearing potential. Participants not of childbearing potential include post-menopausal females (defined as having a history of amenorrhea for at least one year) or a documented status as being surgically sterile (hysterectomy, bilateral oophorectomy, tubal ligation/salpingectomy, or permanently implanted contraceptive device placement); **True abstinence is complete lack of penile-vaginal intercourse. Periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods; ***Acceptable forms of primary contraception include monogamous relationship with a vasectomized partner who has been vasectomized for 180 days or more prior to the participant's vaccination; intrauterine devices; birth control pills; and injectable/implantable/insertable/transdermal hormonal birth control products. Participants must have used >/=1 acceptable primary form of contraception for at least 30 days prior to vaccination and agree to continue >/=1 acceptable primary form of contraception through 60 days after last vaccination
  • Must agree to refrain from donating blood or blood products during the first 6 months of the study
  • Body mass index (BMI) 18 kg/m\^2 to 35 kg/m\^2, inclusive, and a weight of 130 kg or less at the time of screening

Who cannot take part

  • Positive pregnancy test at screening or prior to vaccine dose
  • Has a significant acute illness (with or without fever), as determined by the site PI or appropriate sub-investigator, within 72 hours prior to dosing* *If the participant meets all other eligibility criteria, they may be enrolled and dosed once they meet this eligibility criterion. If the illness resolves within the 28-day screening window, they do not need to be rescreened, otherwise they will need to be rescreened
  • Currently enrolled in or plans to participate in another clinical trial with an investigational agent
  • Received any live-attenuated or mRNA vaccine in the 28 days prior or any other vaccine in the 14 days prior to study vaccination
  • Has used any prohibited medication within 30 days prior to Day 1 or plans to use prohibited medications*** through Day 57; ***Prohibited medications include systemic immunosuppressive drugs, immune modulators (except acetaminophen or non-steroidal anti-inflammatory drugs), oral corticosteroids, and systemic antineoplastic agents. Topical, inhaled, and intranasal steroids, as well as topical anti-neoplastic agents are acceptable
  • Prior receipt of an influenza A/H5 vaccine
  • Presence of a significant psychiatric condition that, in the opinion of the site Principal Investigator (PI) or appropriate sub-investigator, precludes study participation
  • History of drug abuse or alcohol abuse within 6 months of enrollment that, in the opinion of the site PI or appropriate sub-investigator, precludes study participation
  • Has a history of anaphylaxis to any drug compound, vaccine, food, or other substance, unless approved by the Investigator (or designee)**; **Sensitivity to components of the study product is exclusionary
  • Abnormal heart rate (Grade 2 or higher) at time of vaccination
  • Known and current human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection, based on medical history
  • History of myocarditis or pericarditis
  • Has any medical disease or condition***** that, in the opinion of the site PI or appropriate sub-investigator, precludes study participation****** *****Medical conditions include, but are not limited to, kidney disease with creatinine clearance < 89 mL/min/1.73 cm2 Chronic Kidney Disease Epidemiology Collaboration method (CKD-EPI); known active liver disease; ischemic heart disease, clinically significant cardiac conduction disorder, arrythmia requiring treatment, congenital long QT syndrome, uncompensated heart failure; diabetes requiring insulin; neuropathy or myopathy; history of Guillain-Barré Syndrome; and malignancy (not including squamous cell skin cancer, basal cell skin cancer, or cervical lowgrade squamous intraepithelial lesions) ******Participation may be precluded due to safety concern or inability to adequately evaluate clinical trial endpoints
  • Participant who is lactating
  • Abnormal blood pressure or temperature (Grade 1 or higher) at time of vaccination; ****Grade 1 or higher is equivalent to: Systolic blood pressure (SBP) > 140 mmHg or < 90 mmHg Diastolic blood pressure (DBP) > 90 mmHg Oral temperature >/= 38.0 degrees Celsius (100.4 degrees Fahrenheit)
  • Extended exposure (e.g., occupational or home exposure) to cattle or poultry since March 1, 2024
  • Ingestion of non-pasteurized milk since March 1, 2024, or plans to drink non-pasteurized milk during participation in the trial

Where in United States

  • Duke Vaccine and Trials UnitDurham, United States
  • Baylor College of MedicineHouston, United States
  • Vanderbilt University Medical CenterNashville, United States

About the trial

What the trial wants to find out

This is a phase 1, multicenter, randomized, double-blind trial of two influenza A/H5 mRNA-based vaccines on healthy adult participants, 18-49 years of age. Stage 1 will serve as the open-label, dose finding stage. The first 10 participants will receive 12.5 mcg of H5 AC-Anhui RNA vaccine (Group 1), and the second 10 participants will receive 25 mcg of H5 AC-Anhui RNA vaccine (Group 2). After Protocol Safety Review Team (PSRT) review of reactogenicity and safety data through Day 8 for both Groups 1 and 2, another 10 participants may be enrolled to receive 50 mcg of H5 AC-Anhui RNA vaccine (Group 3). Safety data from 7 days after dose 2 for Groups 1 and 2 participants will be reviewed by the PSRT prior to clearing Group 3 participants for the second dose of vaccine. Individual participants will be followed for approximately 6 months following the second dose of vaccine. The primary objective is to assess the safety of two doses of H5 AC-Anhui RNA vaccine or H5-Astrakhan RNA vaccine administered intramuscularly in healthy adults (18-49 years). Once the Day 36 data from Group 3 are reviewed by the PSRT, a dose will be chosen (12.5 mcg, 25 mcg, or 50 mcg) for advancement to Stage 2 where 50 participants will be randomized 1:1 to receive either H5 AC-Anhui RNA (Group 4) or H5 Astrakhan RNA (Group 5) in a double-blinded manner.

The 5 groups in the trial

  • Stage 1 Group 1Treatment being tested

    Healthy male and non-pregnant female participants, ages 18 to 49, will be administered two intramuscular doses of H5 Antigenically Central (AC)-Anhui RNA Vaccine at 12.5 mcg on days 1 and 29. N=10

    Treatment: H5 AC-Anhui RNA Vaccine and Sodium Chloride, 0.9%

  • Stage 1 Group 2Treatment being tested

    Healthy male and non-pregnant female participants, ages 18 to 49, will be administered two intramuscular doses of H5 AC-Anhui RNA Vaccine at 25 mcg on days 1 and 29. N=10

    Treatment: H5 AC-Anhui RNA Vaccine and Sodium Chloride, 0.9%

  • Stage 1 Group 3Treatment being tested

    After the Protocol Safety Review Team (PSRT) reviews the reactogenicity and safety data, through Day 8, for both Stage 1 Group 1 and Stage 1 Group 2, healthy male and non-pregnant female participants, ages 18 to 49, will be administered two intramuscular doses of H5 AC-Anhui RNA Vaccine at 50 mcg on days 1 and 29. N=10

    Treatment: H5 AC-Anhui RNA Vaccine and Sodium Chloride, 0.9%

  • Stage 2 Group 4Treatment being tested

    Following the Day 36 Stage 1 Group 3 data review by the Protocol Safety Review Team (PSRT), healthy male and non-pregnant female participants, ages 18 to 49, will be administered two intramuscular doses of H5 AC-Anhui RNA Vaccine at 25 mcg on days 1 and 29. N=25

    Treatment: H5 AC-Anhui RNA Vaccine and Sodium Chloride, 0.9%

  • Stage 2 Group 5Treatment being tested

    Following the Day 36 Stage 1 Group 3 data review by the Protocol Safety Review Team (PSRT), healthy male and non-pregnant female participants, ages 18 to 49, will be administered two intramuscular doses of H5 Astrakhan RNA Vaccine at 25 mcg on days 1 and 29. N=25

    Treatment: H5 Astrakhan RNA Vaccine and Sodium Chloride, 0.9%

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 1 Study to Evaluate the Safety and Immunogenicity of Two Doses of a Novel H5 Antigenically Central (AC)-Anhui mRNA-LNP Vaccine in Healthy Adults
Record updated
12 June 2026